

SB0306/423027/1

BY: Finance Committee

AMENDMENTS TO SENATE BILL 306  
(First Reading File Bill)

AMENDMENT NO. 1

On page 1, in line 6, after “services” insert “under certain circumstances”; and in the same line, after “indexes;” insert “requiring the Maryland Prescription Drug Affordability Board to conduct a certain study”.

AMENDMENT NO. 2

On page 2, in line 5, strike “**THE**” and substitute “**NOT LATER THAN SEPTEMBER 1, 2026, THE**”; in line 7, after “**SUBTITLE**” insert “**PROVIDED BY A PERSON WHO HOLDS A PHARMACY PERMIT UNDER TITLE 12, SUBTITLE 4 OF THE HEALTH OCCUPATIONS ARTICLE**”; in line 11, after “**INCLUDE**” insert “:

**1.**”;

in the same line, after “**FEES**” insert “**; AND**

**2. ANY OTHER PERCENTAGE INCREASE OR DECREASE DETERMINED BY THE COMMISSION**”;

after line 11, insert:

**“(III) THIS PARAGRAPH DOES NOT PROHIBIT AN INSURANCE CARRIER OR EMPLOYER FROM CONTRACTING WITH A PHARMACY BENEFITS MANAGER, A NETWORK OF PHARMACIES, OR DISPENSING PROVIDERS:**

**1. FOR REIMBURSEMENT RATES DIFFERENT THAN THOSE ESTABLISHED BY THE COMMISSION; OR**

**2. TO USE A PRICING INDEX OR INDEXES DIFFERENT THAN THOSE SELECTED BY THE COMMISSION.**”;

after line 20, insert:

“SECTION 2. AND BE IT FURTHER ENACTED, That:

(a) The Maryland Prescription Drug Affordability Board:

(1) shall conduct a study on prescription drug affordability challenges related to workers’ compensation claims that includes:

(i) an overview of prescription drug prescribing and billing practices and trends that are specialized to the workers’ compensation market;

(ii) research into specific prescribing, billing, and dispensing practices, including:

1. prescribing high cost formulations and compounded formulations of commonly available drugs;

2. billing and dispensing from entities that do not bill or provide services in the health insurance market; and

3. billing practices using billing codes without standardized pricing metrics; and

(iii) making recommendations, if applicable, for policies to address identified affordability challenges; and

(2) may require, subject to applicable federal and State laws, entities that pay, prescribe, bill, and dispense prescription drugs under workers' compensation claims to report information to the Board as necessary to complete the study.

(b) On or before March 1, 2026, the Prescription Drug Affordability Board shall report its findings and any recommendations to the Senate Finance Committee and the House Economic Matters Committee, in accordance with § 2-1257 of the State Government Article.”;

in line 21, strike “2.” and substitute “3.”; and in line 22, strike “October” and substitute “July”.